Characterizing the gut microbiota in patients with chronic kidney disease

Hu, Xiaofang; Ouyang, Shaxi; Xie, Yanjun; Gong, Zhicheng; Du, Jie

doi:10.1080/00325481.2020.1744335

Cited by 72 publications

(62 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirteen (15/25) studies examined the a-diversity of fecal microbiota based on observed species, Chao1, phylogenetic diversity whole tree, Shannon, or Sobs indexes (Table S4), of which six focused on ESRD [21][22][23][24][25][26][27]. Six (6/9) and four studies (4/6) that included patients with CKD [19,23,25,[27][28][29] and ESRD [23][24][25][26] demonstrated that the a-diversity of gut microbiota was significantly lower in patients than in healthy controls, respectively. Three (3/9) and two studies (2/6) that focused on CKD [17,30,31] or ESRD [21,22] suggested that a-diversity was similar in patients and healthy controls, respectively.…”

Section: Alpha (A)-diversitymentioning

confidence: 99%

“…Of 15 studies, 11 studies were conducted in China, and four (4/11) studies focused on ESRD. Five (5/7) studies [18,[27][28][29]32] carried in China showed that the a-diversity of gut microbiota was significantly lower in CKD patients than in healthy controls; one study [19] conducted in Italy showed that the a-diversity of gut microbiota in IgAN patients was significantly lower than in healthy controls, while another study [31] carried in Italy focused on CKD patients reported an opposite result. Three (3/4) studies [24][25][26] carried in China and one study [23] carried in Austria revealed that the a-diversity of gut microbiota was significantly decreased in ESRD patients than in healthy controls; while the study [21] conducted in the US reported a different result.…”

Section: Alpha (A)-diversitymentioning

confidence: 99%

“…Of 17 studies, 13 studies were conducted in China, and four (4/13) studies focused on ESRD. Nine (9/9) studies [17,18,20,[27][28][29][30]32,33] carried in China showed that the b-diversity of gut microbiota in CKD patients was significantly distinct from that of healthy controls; one study [19] carried in Italy revealed that the b-diversity of gut microbiota in IgAN patients was significantly distinct from that of healthy controls, while another study [31] carried in Italy reported an opposite result. Three (3/4) studies [24][25][26] carried in China reported that the b-diversity of gut microbiota in the ESRD patients was significantly distinct from that of healthy controls.…”

Section: Beta (B)-diversitymentioning

confidence: 99%

“…Twelve (12/25) studies analyzed the relatively distinct taxa at the phylum level (Table S6), of which two studies (2/10) focused on ESRD [24,25]. Six (6/10) and three (3/10) studies demonstrated that Proteobacteria [24,25,[27][28][29]33] and Fusobacteria [18,27,34] were more abundant, while two (2/10) studies [18,29] showed that the abundance of Synergistetes in patients with CKD was less than that in controls. The abundance of Firmicutes, Bacteroidetes, and Actinobacteria in patients with CKD was inconsistent when compared to controls.…”

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

“…Of 12 studies, 10 studies were conducted in China, and two (2/10) studies focused on ESRD. Five (5/8), two (2/8), and two (2/8) studies demonstrated that Proteobacteria [20,[27][28][29]33], Fusobacteria [18,27], and Bacteroidetes [17,33] were more abundant, while four (4/8) and two (2/8) studies revealed that Firmicutes [17,27,28,33] and Synergistetes [18,29] were less abundant in Chinese CKD patients compared with healthy controls, respectively. However, the two studies conducted in the US [34] and Italy [19] did not identify any taxa with the same alteration in CKD patients.…”

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

See 4 more Smart Citations

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

et al. 2021

View full text Add to dashboard Cite

Section: Alpha (A)-diversitymentioning

confidence: 99%

Section: Alpha (A)-diversitymentioning

confidence: 99%

Section: Beta (B)-diversitymentioning

confidence: 99%

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

See 3 more Smart Citations

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

et al. 2021

View full text Add to dashboard Cite

The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes

Tremlett

Zhu

Arnold

et al. 2021

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective: To examine the gut microbiota in individuals with and without pediatric-onset multiple sclerosis (MS). Methods: We compared stool-derived microbiota of Canadian Pediatric Demyelinating Disease Network study participants ≤21 years old, with MS (disease-modifying drug [DMD] exposed and na€ ıve) or monophasic acquired demyelinating syndrome [monoADS] (symptom onset <18 years), and unaffected controls. All were ≥30 days without antibiotics or corticosteroids. V4 region 16S RNA gene-derived amplicon sequence variants (Illumina MiSeq) were assessed using negative binomial regression and network analyses; rate ratios were age-and sex-adjusted (aRR). Results: Thirty-two MS, 41 monoADS (symptom onset [mean] = 14.0 and 6.9 years) and 36 control participants were included; 75%/56%/58% were female, with mean ages at stool sample = 16.5/13.8/15.1 years, respectively. Nine MS cases (28%) were DMD-na€ ıve. Although microbiota diversity (alpha, beta) did not differ between participants (p > 0.1), taxa-level and gut community networks did. MS (vs. mono-ADS) exhibited > fourfold higher relative abundance of the superphylum Patescibacteria (aRR = 4.2;95%CI:1.6-11.2, p = 0.004, Q = 0.01), and lower abundances of short-chain fatty acid (SCFA)-producing Lachnospiraceae (Anaerosporobacter) and Ruminococcaceae (p, Q < 0.05). DMD-na€ ıve MS cases were depleted for Clostridiales vadin-BB60 (unnamed species) versus either DMD-exposed, controls (p, Q < 0.01), or monoADS (p = 0.001, Q = 0.06) and exhibited altered community connectedness (p < 10 À9 Kruskal-Wallis), with SCFA-producing taxa underrepresented. Consistent taxa-level findings from an independent US Network of Pediatric MS Centers case/control (n = 51/42) cohort included >eightfold higher abundance for Candidatus Stoquefichus and 2252

show abstract

Study of Serum Metabolic Biomarkers and Prediction Models of Cantharidin‐Induced Nephrotoxicity in Rats Based on Dynamic Metabolomics

Cheng,

Feng,

Tian

et al. 2024

J of Applied Toxicology

View full text Add to dashboard Cite

The clinical application of cantharidin (CTD) is seriously limited due to its nephrotoxicity. Therefore, this study aims to investigate sensitive biomarkers for the evaluation and prediction of nephrotoxicity induced by CTD in rat. A total of 80 rats were randomly divided into four groups: control group and three doses of CTD groups. After 0, 1, 5, 15, and 28 days of intragastric administration, rat serum and urine were collected for biochemical indexes, then serum was used for metabolomic analyses, and rat kidney was collected for pathological and ultrastructural observation. The levels of serum crea (Scr), blood urea nitrogen (BUN), urea, urine crea (Ucrea), and urinary microalbumin (UmALB) were significantly increased after administration of different doses of CTD (p < 0.05). Additionally, histopathology and cell ultrastructure observation of kidney showed significant cell inflammatory infiltration and glomerular edema. Seven metabolic biomarkers including 6‐hydroxymelatonin were significantly disturbed by CTD. The CatBoost Classifier prediction model was used to establish the CTD nephrotoxicity prediction model, and the prediction accuracy and precision were 0.645 and 0.640, respectively. Moreover, 6‐hydroxymelatonin was found to be most useful biomarkers for evaluating the CTD nephrotoxicity. Finally, the seven metabolic biomarkers were found mainly involved in pyruvate metabolism, pantothenate and CoA biosynthesis.

show abstract

Characterizing the gut microbiota in patients with chronic kidney disease

Cited by 72 publications

References 69 publications

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes

Study of Serum Metabolic Biomarkers and Prediction Models of Cantharidin‐Induced Nephrotoxicity in Rats Based on Dynamic Metabolomics

Contact Info

Product

Resources

About